Silvion has demonstrated:

      -Broad spectrum antimicrobial coverage against Methicillin-resistant Staphylococcus

        aureus (MRSA), Vancomycin-resistant Enterococcus faecalis (VRE) and multi-drug

       resistant Pseudomonas sp. and Acinetobacter baumannii (Iraqi)

     - Effectiveness against common gram positive and gram negative bacterial

       pathogens associated with nosocomial (hospital required) infections

      -Biocompatibility resulting in increased patient comfort

      -Dissolution of developing microbial resistance

      -Low probability of developing microbial resistance

Indications for Silvion include: 

1st and 2nd Degree Burns, Stage I to Stage IV Pressure Ulcers, Venous Stasis Ulcers, Diabetic Ulcers, Post Surgical Wounds, Dermal Lesions, Abrasions and Skin Irritations.

Potentiator induced holes in the membrane resulting in cytoplasmic leakage and bacterial death

Normal “intact” Methicillin resistant bacteria Staphylococcus aureus (MRSA)   

Normal “intact” colony of multi-drug resistant Pseudomonas sp

Silvion causes colony collapse and microbial death (bacteria are pyknotic and agglutinated)

Normal “intact” colony of Methicillin resistant Staphylococcus aureus showing well organized Biofilm

Silvion destroys the Biofilm facilitating colony collapse and microbial death (bacteria are pyknotic and agglutinated)

Copyright 2017. All Rights Reserved

The prevention or resolution of skin or wound colonization by pathogenic microorganism has and continue to have important health repercussions. The use and misuse of antimicrobial agents continues to support the evolution of multi-drug resistant organisms that have the potential of causing significant morbidity and mortality including Methicillin resistant Staphylococcus aureus (MRSA), Vancomycin resistant Enterococcus faecalis (VRE) and multi-drug resistant Pseudomonas aeruginosa.

Numerous reports in the media and professional medical literature have expressed grave concerns about the effectiveness of currently available antibiotics against multi-drug resistant bacteria. Some strains of pathogenic bacteria have demonstrated rapidly evolving defensive strategies that render antibiotics worthless. One defensive strategy used by  microbes is to secrete a substance known as biofilm, which provides a protective shield effectively blocking antimicrobials from contacting the microbe.

An innovative technology, based upon research conducted by the Emerging Diseases Research Group at the University of Georgia, has been developed that significantly enhances and potentiates the killing activity of topical antimicrobials. This new class of antimicrobials has been proven to destroy the protective barrier of biofilms as well as the integrity and functionality of the microbe’s cellular membrane. In vitro testing has shown that microbes that quickly develop resistance to antimicrobials in vivo, are unlikely to remain resistant or develop resistance to Potentiated antimicrobials.

Silvion is one of the first products incorporating this revolutionary  Potentiated antimicrobial technology to receive FDA clearance for professional use. Silvion Does Not Contain Alcohol, Triclosan nor Benzoyl Chloride.

®

Molecular Therapeutics, Silvion, SilvaKlenz, Potentiator and Potentiated are registered trademarks.

Molecular Therapeutics, LLC  111 Riverbend Rd, Suite 264 Athens, GA 30602 Contact Us